Alector, Inc. (NASDAQ:ALEC) Shares Bought by Wells Fargo & Company MN

Wells Fargo & Company MN lifted its stake in Alector, Inc. (NASDAQ:ALEC) by 50.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 37,966 shares of the company’s stock after acquiring an additional 12,653 shares during the quarter. Wells Fargo & Company MN’s holdings in Alector were worth $72,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Barclays PLC increased its stake in Alector by 132.4% during the 3rd quarter. Barclays PLC now owns 176,800 shares of the company’s stock worth $824,000 after buying an additional 100,731 shares during the period. Los Angeles Capital Management LLC increased its stake in Alector by 61.2% during the 4th quarter. Los Angeles Capital Management LLC now owns 90,736 shares of the company’s stock worth $171,000 after buying an additional 34,450 shares during the period. RPO LLC purchased a new stake in Alector during the 4th quarter worth approximately $50,000. Apollon Wealth Management LLC purchased a new stake in Alector during the 4th quarter worth approximately $47,000. Finally, Intech Investment Management LLC increased its stake in Alector by 83.5% during the 4th quarter. Intech Investment Management LLC now owns 35,382 shares of the company’s stock worth $67,000 after buying an additional 16,096 shares during the period. 85.83% of the stock is currently owned by institutional investors and hedge funds.

Alector Price Performance

NASDAQ ALEC opened at $1.20 on Tuesday. The firm’s fifty day moving average price is $1.18 and its 200 day moving average price is $2.06. The company has a market capitalization of $119.99 million, a price-to-earnings ratio of -0.71 and a beta of 0.76. Alector, Inc. has a 12 month low of $0.87 and a 12 month high of $6.78.

Alector (NASDAQ:ALEC) last posted its earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.59. The firm had revenue of $54.24 million for the quarter, compared to the consensus estimate of $20.41 million. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. As a group, sell-side analysts forecast that Alector, Inc. will post -1.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ALEC shares. Morgan Stanley reaffirmed an “underweight” rating and set a $1.50 target price (down from $3.00) on shares of Alector in a research note on Friday, March 7th. HC Wainwright upped their target price on shares of Alector from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Alector has an average rating of “Hold” and a consensus price target of $4.00.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.